How much weight can I lose with Zepbound?

In the SURMOUNT-1 trial, participants lost an average of 15% (5 mg dose), 19.5% (10 mg), and 22.5% (15 mg) of body weight over 72 weeks. However, individual results vary widely — about one-third of participants on the highest dose lost 25% or more, while some had more modest results. Zepbound works best when combined with a reduced-calorie diet and regular physical activity.

How is Zepbound different from Wegovy?

Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, while Wegovy (semaglutide) activates only GLP-1 receptors. In direct comparison trials, tirzepatide produced greater weight loss than semaglutide. Both are effective, and the choice depends on individual response, side effect profile, insurance coverage, and your doctor's assessment.

What happens if I stop taking Zepbound?

The SURMOUNT-3 trial showed that participants who discontinued tirzepatide after initial weight loss regained a significant portion of the lost weight within one year. The appetite-suppressing effects reverse when the medication is stopped. Zepbound is intended as a long-term, potentially indefinite treatment for chronic weight management.

Will my insurance cover Zepbound?

Coverage varies by plan. Many commercial insurers have begun covering Zepbound with prior authorization (typically requiring documented BMI criteria and sometimes failure of diet/exercise programs). Medicare Part D currently has limited coverage for anti-obesity medications. Check with your insurer and explore the manufacturer's savings programs if out-of-pocket costs are prohibitive.

What to Expect When Starting Tirzepatide (Zepbound)

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity ^[1]. It is the same active ingredient as Mounjaro but indicated and dosed specifically for weight loss. In the SURMOUNT-1 trial, participants lost an average of 22.5% of body weight at the highest dose over 72 weeks — the largest weight loss ever demonstrated with a pharmacotherapy ^[3].

Week-by-week timeline

Week 1-4GI side effects are usually mild to moderate and improve within 1-2 weeks. Eating smaller meals is the most effective strategy.

Starting at 2.5 mg Weekly

You begin with 2.5 mg subcutaneous injection once weekly [1]. This dose is for tolerability and is not yet therapeutic for weight loss. Nausea, diarrhea, and decreased appetite are the most common side effects (12-18% each), usually peaking in the first 1-2 weeks at each new dose [2]. Many patients notice appetite reduction within the first 1-2 weeks even at this low dose. Some early weight loss (1-2 kg) may occur from reduced caloric intake.

Month 2-3If GI side effects are intolerable at a new dose, your doctor may extend the current dose level for an additional 4 weeks before escalating.

Escalation to 5 mg and 7.5 mg Weekly

The dose increases to 5 mg at month 2 and potentially 7.5 mg at month 3, with escalation every 4 weeks [1]. Appetite suppression intensifies, and you may find that meal portions naturally decrease substantially. GI symptoms may recur with each escalation but typically settle within 1-2 weeks. Weight loss accelerates — in clinical trials, participants lost approximately 5-8% of body weight by the 3-month mark at mid-range doses [3]. Food preferences may shift, with reduced interest in calorie-dense foods.

Month 4-5Weight loss of this magnitude can require adjustments to other medications (blood pressure, diabetes drugs). Keep all healthcare providers informed of your progress.

Escalation to 10-15 mg Weekly

The dose continues to escalate toward the target range of 10-15 mg weekly [1]. The SURMOUNT-1 trial demonstrated average weight losses of 19.5% (10 mg) and 22.5% (15 mg) over 72 weeks [3]. Significant physical changes are now apparent — improved mobility, reduced joint pain, better sleep quality, and improved metabolic markers (blood pressure, lipids, blood sugar). GI side effects have usually diminished at this stage as the body has adapted through gradual escalation.

Month 6+Weight loss plateaus are normal and expected. Maintaining a 15-20% weight loss is a major achievement with substantial health benefits.

Maintenance at Target Dose

At the target dose (typically 10 or 15 mg weekly), weight loss continues gradually for 12-18 months before plateauing [1]. The SURMOUNT-3 trial demonstrated that continuing tirzepatide after an initial weight loss phase maintained the lost weight, while switching to placebo resulted in regain [2]. This medication is intended for long-term or indefinite use. GI side effects are minimal at this stage. Focus shifts to maintaining healthy dietary patterns and physical activity to support the metabolic changes.

When to call your doctor

Contact your healthcare provider if you experience:

Severe, persistent abdominal pain — especially if radiating to the back, which may indicate pancreatitis [1]
Signs of allergic reaction: rash, itching, swelling of face/lips/tongue, difficulty breathing [1]
Persistent vomiting or inability to keep down fluids for more than 24 hours, risking dehydration [1]
Symptoms of gallbladder disease: severe pain in upper right abdomen, nausea, fever, or jaundice — gallstones occur more frequently during rapid weight loss [1]
A lump or swelling in the neck, hoarseness, difficulty swallowing — related to the boxed warning about thyroid C-cell tumors in rodent studies [1]
Mental health changes: new or worsening depression, suicidal thoughts, or unusual mood or behavior changes [1]

Tips for getting started

Inject Zepbound on the same day each week, at any time of day, with or without meals. Rotate injection sites (abdomen, thigh, upper arm). Prioritize protein intake (aim for 1.0-1.2 g per kg of body weight daily) to preserve lean muscle mass during rapid weight loss ^[2]. Stay well hydrated — at least 64 oz of water daily. Engage in both aerobic exercise and resistance training to support metabolic health and body composition. Eat smaller, frequent meals during dose escalation to minimize nausea. Store unused pens in the refrigerator; an in-use pen can be kept at room temperature for up to 21 days ^[1].

Frequently asked questions

More about Tirzepatide (Zepbound)

Tirzepatide (Zepbound) drug guideSide effects, dosage, interactions, and more Semaglutide (Wegovy) vs Tirzepatide (Zepbound)Compare these medications Tirzepatide (Mounjaro) vs Tirzepatide (Zepbound)Compare these medications Metformin & Tirzepatide (Zepbound)Interaction details

References

[Regulatory] Zepbound (tirzepatide) injection FDA Prescribing Information. Eli Lilly. Revised 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215981s003lbl.pdf Accessed 2025-01-15.
[Regulatory] Tirzepatide. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/ Accessed 2025-01-15.
[Clinical] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026